Loading
Companies with drugs that might work together rarely test them because the legal negotiation takes longer than the trial. A pre-written standard contract would fix that.
The CRUK Combinations Alliance and NCI CTEP show that a neutral third party with template agreements can run combination studies across companies. Extending this to an industry-wide, pre-negotiated 'combination clinical trial agreement' (like the standard licences in software) covering supply, data, publication, IP on combination findings and a default revenue rule would remove the largest non-scientific barrier.
Shares Secrecy and intellectual property block collaboration, Too many combinations to test, National Cancer Institute (NIH).
Shares Secrecy and intellectual property block collaboration, Too many combinations to test.
Shares Secrecy and intellectual property block collaboration, Cancer Research UK.
Shares Too many combinations to test, Cancer Research UK, National Cancer Institute (NIH).